India’s Sun Pharmaceutical Industries will buy Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion including debt, the companies said on Sunday.
Under the definitive agreement, Sun Pharma will buy all the outstanding shares of Organon for $14.00 per share in cash, the companies said in a joint statement.
The deal would give Sun Pharma full ownership of Organon, which was spun off from Merck in 2021, and focuses on women’s health, biosimilars and established medicines.
Reuters
